Larotrectinib sulfate

Overview

Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase ( TRK ) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms ( TRKA , B, and C).

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Trk Receptor | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-12866A
• CAS No.: 1223405-08-0
• Molecular Formula: C21H24F2N6O6S
• Molecular Weight: 526.51
• Purity: 99.02%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
• Solubility: ≥ 3.25 mg/mL (6.17 mM); Clear solution
• Availability: In-stock

Source

Original product source